{"id":1008,"date":"2022-09-01T03:16:16","date_gmt":"2022-09-01T03:16:16","guid":{"rendered":"http:\/\/eye-connect.org\/dr\/?page_id=1008"},"modified":"2025-09-21T19:40:42","modified_gmt":"2025-09-21T19:40:42","slug":"module-2-accredited-activities","status":"publish","type":"page","link":"https:\/\/eye-connect.org\/dr\/module-2-accredited-activities\/","title":{"rendered":"Module 2 Accredited Activities"},"content":{"rendered":"<section class=\"wpb-content-wrapper\"><p>[vc_row css_animation=&#8221;&#8221; row_type=&#8221;row&#8221; use_row_as_full_screen_section=&#8221;no&#8221; type=&#8221;full_width&#8221; angled_section=&#8221;no&#8221; text_align=&#8221;left&#8221; background_image_as_pattern=&#8221;without_pattern&#8221; css=&#8221;.vc_custom_1660776373517{padding-top: 3% !important;padding-bottom: 3% !important;background-color: #ffffff !important;}&#8221; z_index=&#8221;&#8221;][vc_column][vc_raw_html]JTNDcCUzRSU1QmxvZ28tc2hvd2Nhc2UlMjBpZCUzRCUyMjE4MSUyMiUyMHRpdGxlJTNEJTIyUGFydG5lciUyMExvZ28lMjIlNUQlM0MlMkZwJTNF[\/vc_raw_html][vc_empty_space height=&#8221;20px&#8221;][vc_empty_space height=&#8221;20px&#8221;]\n\t\t\t<!-- START Module 2 Header PNG REVOLUTION SLIDER 6.6.12 --><p class=\"rs-p-wp-fix\"><\/p>\n\t\t\t<rs-module-wrap id=\"rev_slider_22_1_wrapper\" data-source=\"gallery\" style=\"visibility:hidden;background:transparent;padding:0;\">\n\t\t\t\t<rs-module id=\"rev_slider_22_1\" style=\"\" data-version=\"6.6.12\">\n\t\t\t\t\t<rs-slides style=\"overflow: hidden; position: absolute;\">\n\t\t\t\t\t\t<rs-slide style=\"position: absolute;\" data-key=\"rs-49\" data-title=\"Module 1 Header 2\" data-anim=\"adpr:false;\" data-in=\"o:0;\" data-out=\"a:false;\">\n\t\t\t\t\t\t\t<img src=\"\/\/eye-connect.org\/dr\/wp-content\/plugins\/revslider\/public\/assets\/assets\/dummy.png\" alt=\"Module 2 Activities\" title=\"module2-banner\" width=\"1240\" height=\"640\" class=\"rev-slidebg tp-rs-img rs-lazyload\" data-lazyload=\"\/\/eye-connect.org\/dr\/wp-content\/uploads\/2022\/09\/module2-banner.png\" data-no-retina>\n<!--\n\t\t\t\t\t\t\t--><rs-layer\n\t\t\t\t\t\t\t\tid=\"slider-22-slide-49-layer-0\" \n\t\t\t\t\t\t\t\tdata-type=\"text\"\n\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\tdata-xy=\"xo:495px,443px,332px,152px;yo:399px,328px,285px,267px;\"\n\t\t\t\t\t\t\t\tdata-text=\"w:nowrap;s:50,32,24,24;l:92,75,56,34;fw:300,300,300,400;a:right;\"\n\t\t\t\t\t\t\t\tdata-dim=\"w:640px,528px,401px,290px;\"\n\t\t\t\t\t\t\t\tdata-frame_999=\"o:0;st:w;\"\n\t\t\t\t\t\t\t\tstyle=\"z-index:11;font-family:'Lato';\"\n\t\t\t\t\t\t\t>Leveraging Evidence  \n\t\t\t\t\t\t\t<\/rs-layer><!--\n\n\t\t\t\t\t\t\t--><rs-layer\n\t\t\t\t\t\t\t\tid=\"slider-22-slide-49-layer-1\" \n\t\t\t\t\t\t\t\tdata-type=\"text\"\n\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\tdata-xy=\"xo:495px,443px,332px,193px;yo:452px,367px,315px,295px;\"\n\t\t\t\t\t\t\t\tdata-text=\"w:nowrap;s:50,32,24,24;l:92,75,56,34;fw:300,300,300,400;a:right;\"\n\t\t\t\t\t\t\t\tdata-dim=\"w:640px,528px,401px,247px;\"\n\t\t\t\t\t\t\t\tdata-frame_999=\"o:0;st:w;\"\n\t\t\t\t\t\t\t\tstyle=\"z-index:10;font-family:'Lato';\"\n\t\t\t\t\t\t\t>in the Treatment of \n\t\t\t\t\t\t\t<\/rs-layer><!--\n\n\t\t\t\t\t\t\t--><rs-layer\n\t\t\t\t\t\t\t\tid=\"slider-22-slide-49-layer-2\" \n\t\t\t\t\t\t\t\tdata-type=\"text\"\n\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\tdata-xy=\"xo:488px,424px,318px,120px;yo:508px,406px,348px,322px;\"\n\t\t\t\t\t\t\t\tdata-text=\"w:nowrap;s:50,32,24,24;l:92,75,56,34;fw:700;a:right;\"\n\t\t\t\t\t\t\t\tdata-dim=\"w:640px,547px,415px,318px;\"\n\t\t\t\t\t\t\t\tdata-frame_999=\"o:0;st:w;\"\n\t\t\t\t\t\t\t\tstyle=\"z-index:9;font-family:'Lato';\"\n\t\t\t\t\t\t\t>Patients With DR\/DME \n\t\t\t\t\t\t\t<\/rs-layer><!--\n\n\t\t\t\t\t\t\t--><rs-layer\n\t\t\t\t\t\t\t\tid=\"slider-22-slide-49-layer-3\" \n\t\t\t\t\t\t\t\tdata-type=\"shape\"\n\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\tdata-xy=\"xo:472px,420px,396px,110px;yo:413px,344px,293px,267px;\"\n\t\t\t\t\t\t\t\tdata-text=\"w:normal;s:20,16,12,7;l:0,20,15,9;\"\n\t\t\t\t\t\t\t\tdata-dim=\"w:681px,562px,348px,347px;h:180px,127px,108px,91px;\"\n\t\t\t\t\t\t\t\tdata-frame_999=\"o:0;st:w;\"\n\t\t\t\t\t\t\t\tstyle=\"z-index:8;background-color:rgba(0,0,0,0.5);\"\n\t\t\t\t\t\t\t> \n\t\t\t\t\t\t\t<\/rs-layer><!--\n-->\t\t\t\t\t\t<\/rs-slide>\n\t\t\t\t\t<\/rs-slides>\n\t\t\t\t<\/rs-module>\n\t\t\t\t<script>\n\t\t\t\t\tsetREVStartSize({c: 'rev_slider_22_1',rl:[1240,1024,778,480],el:[640,530,450,400],gw:[1240,1024,778,480],gh:[640,530,450,400],type:'hero',justify:'',layout:'fullscreen',offsetContainer:'',offset:'',mh:\"0\"});if (window.RS_MODULES!==undefined && window.RS_MODULES.modules!==undefined && window.RS_MODULES.modules[\"revslider221\"]!==undefined) {window.RS_MODULES.modules[\"revslider221\"].once = false;window.revapi22 = undefined;if (window.RS_MODULES.checkMinimal!==undefined) window.RS_MODULES.checkMinimal()}\n\t\t\t\t<\/script>\n\t\t\t<\/rs-module-wrap>\n\t\t\t<!-- END REVOLUTION SLIDER -->\n[\/vc_column][\/vc_row][vc_row css_animation=&#8221;&#8221; row_type=&#8221;row&#8221; use_row_as_full_screen_section=&#8221;no&#8221; type=&#8221;grid&#8221; angled_section=&#8221;no&#8221; text_align=&#8221;left&#8221; background_image_as_pattern=&#8221;without_pattern&#8221; z_index=&#8221;&#8221; background_color=&#8221;#ffffff&#8221; css=&#8221;.vc_custom_1666279011095{padding-right: 10% !important;padding-left: 10% !important;}&#8221; el_class=&#8221;module-2-list&#8221;][vc_column][vc_column_text]<\/p>\n<div class=\"verticalLine3\">\n<h6><img style=\"margin-top: 10px; margin-right: 10px; float: left;\" src=\"http:\/\/eye-connect.org\/dr\/wp-content\/uploads\/2022\/09\/eye-connect-motif.png\" \/>New data regarding the use of anti-vascular endothelial growth factor (VEGF) prophylaxis in patients with moderate to severe nonproliferative diabetic retinopathy without diabetic macular edema underscore the need for an evidence-based shift to proactive diabetic retinopathy (DR) treatment (rather than \u201cwatch and wait\u201d). Guideline recommendations do not reflect the available treatments, and strategies to reduce anti-VEGF treatment burden (eg, treat-and-extend dosing, high-dose and novel agents, and novel products) continue to evolve and emerge, challenging clinicians to stay current and highlighting the need for individualized treatment and shared decision-making in DR treatment.<\/h6>\n<h6>This collection of activities provides guidance for treatment of DR\/diabetic macular edema (DME) with anti-VEGF agents, strategies to reduce anti-VEGF treatment burden (eg, treat-and-extend dosing, high-dose and novel agents, and novel products), and highlights the need for individualized treatment and shared decision-making in DR treatment.<\/h6>\n<\/div>\n<p>[\/vc_column_text][vc_column_text css=&#8221;.vc_custom_1666105917849{padding-top: 2% !important;}&#8221; el_class=&#8221;module_img&#8221;]<\/p>\n<h1 class=\"qode-info-card-title\" style=\"text-align: left; color: #0d4669;\">Accredited Activities<\/h1>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row css_animation=&#8221;&#8221; row_type=&#8221;row&#8221; use_row_as_full_screen_section=&#8221;no&#8221; type=&#8221;full_width&#8221; angled_section=&#8221;no&#8221; text_align=&#8221;left&#8221; background_image_as_pattern=&#8221;without_pattern&#8221; css=&#8221;.vc_custom_1660794313100{padding-top: 3% !important;padding-right: 10% !important;padding-bottom: 3% !important;padding-left: 10% !important;}&#8221; z_index=&#8221;&#8221; background_image=&#8221;285&#8243;][vc_column][vc_single_image image=&#8221;276&#8243; img_size=&#8221;full&#8221; alignment=&#8221;center&#8221; qode_css_animation=&#8221;&#8221;][vc_empty_space height=&#8221;20px&#8221;][vc_column_text]<\/p>\n<p style=\"text-align: center; color: #ffffff;\">This initiative is provided by Paradigm Medical Communications, LLC.<\/p>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row css_animation=&#8221;&#8221; row_type=&#8221;row&#8221; use_row_as_full_screen_section=&#8221;no&#8221; type=&#8221;full_width&#8221; angled_section=&#8221;no&#8221; text_align=&#8221;left&#8221; background_image_as_pattern=&#8221;without_pattern&#8221; css=&#8221;.vc_custom_1662003009481{background-color: #ffffff !important;}&#8221; z_index=&#8221;&#8221;][vc_column][vc_raw_html]JTNDcCUzRSU1QmxvZ28tc2hvd2Nhc2UlMjBpZCUzRCUyMjE4MSUyMiUyMHRpdGxlJTNEJTIyUGFydG5lciUyMExvZ28lMjIlNUQlM0MlMkZwJTNF[\/vc_raw_html][vc_column_text css=&#8221;.vc_custom_1758326061894{padding-right: 13% !important;padding-bottom: 1% !important;padding-left: 13% !important;}&#8221;]<\/p>\n<p style=\"text-align: center;\">In collaboration with the American Association of Nurse Practitioners, American Academy of Physician Associates, California Academy of Family Physicians, Center for Sustainable Health Care Quality and Equity, Endocrine Society, and National Minority Quality Forum.<\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: center;\"><strong>Supporter Acknowledgment<\/strong><br \/>\nThis initiative is supported by an independent medical educational grant from Regeneron Pharmaceuticals, Inc.<\/p>\n<p>[\/vc_column_text][vc_raw_html]JTNDcCUzRSUzQ2hyJTIwc3R5bGUlM0QlMjIlMjBib3JkZXIlM0ElMjAwJTNCJTIwaGVpZ2h0JTNBJTIwMXB4JTNCJTIwYmFja2dyb3VuZCUzQSUyMCUyMzU4NTg1YSUzQiUyMiUzRSUzQyUyRnAlM0U=[\/vc_raw_html][vc_column_text css=&#8221;.vc_custom_1663071904426{padding-top: 2% !important;padding-right: 15% !important;padding-bottom: 2% !important;padding-left: 15% !important;}&#8221;]<\/p>\n<p style=\"text-align: center;\">Paradigm Medical Communications, LLC presents this resource for educational purposes only. Healthcare professionals are expected to employ their own knowledge and judgement during any discussion with, or treatment of, their patients.<\/p>\n<p style=\"text-align: center;\">For questions, technical support, or playback issues, please email us at <a href=\"mailto:contactus@paradigmmc.com\"><span style=\"color: #58585a; font-weight: normal; text-decoration: underline;\">contactus@paradigmmc.com<\/span><\/a>.<br \/>\n<a href=\"http:\/\/eye-connect.org\/dr\/contact\/\"> <span style=\"color: #58585a; font-weight: normal; text-decoration: underline;\"> Sign up<\/span><\/a> to receive notifications when new activities become available.<\/p>\n<p>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/section>","protected":false},"excerpt":{"rendered":"<p>[vc_row css_animation=&#8221;&#8221; row_type=&#8221;row&#8221; use_row_as_full_screen_section=&#8221;no&#8221; type=&#8221;full_width&#8221; angled_section=&#8221;no&#8221; text_align=&#8221;left&#8221; background_image_as_pattern=&#8221;without_pattern&#8221; css=&#8221;.vc_custom_1660776373517{padding-top: 3% !important;padding-bottom: 3% !important;background-color: #ffffff !important;}&#8221; z_index=&#8221;&#8221;][vc_column][vc_raw_html]JTNDcCUzRSU1QmxvZ28tc2hvd2Nhc2UlMjBpZCUzRCUyMjE4MSUyMiUyMHRpdGxlJTNEJTIyUGFydG5lciUyMExvZ28lMjIlNUQlM0MlMkZwJTNF[\/vc_raw_html][vc_empty_space height=&#8221;20px&#8221;][vc_empty_space height=&#8221;20px&#8221;][\/vc_column][\/vc_row][vc_row css_animation=&#8221;&#8221; row_type=&#8221;row&#8221; use_row_as_full_screen_section=&#8221;no&#8221; type=&#8221;grid&#8221; angled_section=&#8221;no&#8221; text_align=&#8221;left&#8221; background_image_as_pattern=&#8221;without_pattern&#8221; z_index=&#8221;&#8221; background_color=&#8221;#ffffff&#8221; css=&#8221;.vc_custom_1666279011095{padding-right: 10% !important;padding-left: 10% !important;}&#8221; el_class=&#8221;module-2-list&#8221;][vc_column][vc_column_text] New data regarding the use of anti-vascular endothelial growth factor (VEGF) prophylaxis&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"full_width.php","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0},"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/eye-connect.org\/dr\/wp-json\/wp\/v2\/pages\/1008"}],"collection":[{"href":"https:\/\/eye-connect.org\/dr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/eye-connect.org\/dr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/eye-connect.org\/dr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eye-connect.org\/dr\/wp-json\/wp\/v2\/comments?post=1008"}],"version-history":[{"count":55,"href":"https:\/\/eye-connect.org\/dr\/wp-json\/wp\/v2\/pages\/1008\/revisions"}],"predecessor-version":[{"id":2667,"href":"https:\/\/eye-connect.org\/dr\/wp-json\/wp\/v2\/pages\/1008\/revisions\/2667"}],"wp:attachment":[{"href":"https:\/\/eye-connect.org\/dr\/wp-json\/wp\/v2\/media?parent=1008"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}